Pharmaceuticals

Retatrutide

Evidence: Emerging (Phase 3 ongoing)

Mechanism of Action

Triple incretin agonist (GIP/GLP-1/glucagon receptor). Combines appetite suppression and insulin sensitization of GLP-1 with the thermogenic and lipolytic effects of glucagon receptor activation. Produced the greatest weight loss of any anti-obesity agent in Phase 2 trials (~24% at 48 weeks).

Interactions

  • Expected similar to tirzepatide — delays oral medication absorption, potentiates hypoglycemia

Contraindications

  • Not FDA-approved
  • Presumed similar to GLP-1 class — MTC, pancreatitis, severe GI disease

Key Papers

  • Jastreboff et al. 2023 - Retatrutide Phase 2 trial (NEJM)

Buy Retatrutide

If you want to source it today, here’s a fast Amazon search link (we may earn a small commission at no extra cost).

Search on Amazon →
Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should Retatrutide Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds